CLINICAL TRIALS PROFILE FOR DEFLAZACORT

All Clinical Trials for DEFLAZACORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00243789 ↗	Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy	Completed	Cooperative International Neuromuscular Research Group	Phase 1/Phase 2	2005-09-01	The purpose of this study is to see if male children with Duchenne muscular dystrophy (DMD) have changes in strength when given the drug Pentoxifylline as a rescue treatment. A total of 64 subjects are expected to participate through all other centers of the Cooperative International Neuromuscular Research Group (CINRG) worldwide. The primary purpose of this study is to see whether the addition of pentoxifylline to a steroid regimen is effective in treating deteriorating muscle strength by comparing the muscle strength of PTX treated subjects and placebo treated subjects.
NCT00527228 ↗	Deflazacort in Dysferlinopathies	Completed	Ludwig-Maximilians - University of Munich	Phase 2/Phase 3	2003-09-01	The present study is designed to assess the natural history in a one year pre-phase of the trial and evaluate therapeutic efficacy and side effects of deflazacort in LGMD2B/MM patients in a placebo-controlled trial. Furthermore, long-term development of the disease under naturalistic conditions will be documented in a 2-year follow-up after the end of the double-blind treatment phase.
NCT01335295 ↗	Safety Study of Flavocoxid in Duchenne Muscular Dystrophy	Completed	University of Messina	Phase 1	2011-03-01	Objective of this study is to evaluate safety and tolerability of flavocoxid administered at the daily oral dose of 500 or 1000 mg/die for one year in DMD patients, alone or in association with steroids (deflazacort on alternate days) started at least one year before. The investigators will also perform a multidimensional clinical evaluation covering functional and muscle strength and quality of life (QoL)assessments.
NCT01603407 ↗	Finding the Optimum Regimen for Duchenne Muscular Dystrophy	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 3	2013-01-01	The Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR DMD) study will compare three ways of giving corticosteroids to boys with Duchenne muscular dystrophy (DMD) to determine which of the three ways increases muscle strength the most, and which causes the fewest side effects. Using the results of this study, the investigators aim to provide patients and families with clearer information about the best way to take these drugs.
NCT01603407 ↗	Finding the Optimum Regimen for Duchenne Muscular Dystrophy	Completed	Newcastle University	Phase 3	2013-01-01	The Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR DMD) study will compare three ways of giving corticosteroids to boys with Duchenne muscular dystrophy (DMD) to determine which of the three ways increases muscle strength the most, and which causes the fewest side effects. Using the results of this study, the investigators aim to provide patients and families with clearer information about the best way to take these drugs.

Clinical Trial Conditions for DEFLAZACORT

Condition Name

Condition Name for DEFLAZACORT
Intervention	Trials
Duchenne Muscular Dystrophy	8
Healthy Volunteers	3
Limb-Girdle Muscular Dystrophy	2
Healthy	1

Condition MeSH

Condition MeSH for DEFLAZACORT
Intervention	Trials
Muscular Dystrophies	12
Muscular Dystrophy, Duchenne	11
Muscular Dystrophies, Limb-Girdle	3
Kidney Failure, Chronic	1

Clinical Trial Locations for DEFLAZACORT

Trials by Country

Trials by Country for DEFLAZACORT
Location	Trials
United States	117
Canada	11
United Kingdom	8
Italy	8
France	5

Trials by US State

Trials by US State for DEFLAZACORT
Location	Trials
Florida	7
California	7
Pennsylvania	7
Illinois	6
Minnesota	6

Clinical Trial Progress for DEFLAZACORT

Clinical Trial Phase

Clinical Trial Phase for DEFLAZACORT
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	6
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for DEFLAZACORT
Clinical Trial Phase	Trials
Completed	13
Recruiting	3
Active, not recruiting	3

Clinical Trial Sponsors for DEFLAZACORT

Sponsor Name

Sponsor Name for DEFLAZACORT
Sponsor	Trials
PTC Therapeutics	9
Marathon Pharmaceuticals, LLC	7
ICON Development Solutions, LLC	1

Sponsor Type

Sponsor Type for DEFLAZACORT
Sponsor	Trials
Industry	22
Other	16
NIH	1

Deflazacort: Clinical Trials Update, Market Analysis and 5-Year Projection

Last updated: April 27, 2026

What is deflazacort and where is it used clinically?

Deflazacort is an oral corticosteroid used for inflammatory and immune-mediated diseases. Commercial positioning is built around use cases where physicians require systemic glucocorticoid exposure with a perceived differentiated safety profile versus some standard alternatives.

What is the current clinical trial landscape for deflazacort?

Sufficient, trial-level specifics (trial identifiers, phases, timelines, enrollment status, readouts, and sponsor locations) are not provided in the input, and no authoritative trial registry dataset is included. Without verifiable trial records, a complete and accurate “clinical trials update” cannot be produced.

How is deflazacort marketed today, and what are the key demand drivers?

Demand drivers

• Chronic dosing needs: systemic steroids are used long-term in multiple immune and inflammatory indications.
• Pediatric and neuromuscular pathways: deflazacort is used in pediatric care settings in at least some jurisdictions and clinical frameworks.
• Competition from multiple corticosteroid options: market share depends on perceived tolerability, prescriber familiarity, and formulary placement.

Supply and commercialization pattern

• Multi-brand commercialization is typical for corticosteroids across geographies, with pricing and reimbursement shaped by local formularies.
• Patent and regulatory exclusivity status determines the cadence of generic entry, which typically drives volume growth but compresses value.

What is the market size and how does it behave across geographies?

A quantitative market analysis requires current market sizing inputs (global and major-country segments, unit volume, average selling prices, and generic mix). Those figures are not provided in the input, and no cited dataset is supplied. A complete and accurate projection cannot be produced.

Market structure: what moves revenue for deflazacort?

Key variables

• Generic penetration rate by country and timing of patent expirations.
• Reimbursement rules: preferred steroid listing, step therapy, and coverage criteria.
• Formulary inclusion: hospital and outpatient formularies drive repeat prescribing.
• Safety monitoring requirements: adverse event burden can influence switching and persistence.

Competitive set (functional substitutes)

Deflazacort competes with other systemic corticosteroids across shared therapeutic spaces:

• Prednisone and prednisolone
• Methylprednisolone (oral)
• Dexamethasone
• Other locally dominant steroid options by region

Revenue dynamics are shaped by:

• Relative pricing (generic deflazacort vs branded/alternative steroids)
• Uptake due to guideline alignment
• Physician preference and patient history

How should investors and R&D teams underwrite the 5-year outlook?

A defensible projection requires inputs that are not present in the prompt, including:

• Current global sales (by brand and generic)
• Forecast assumptions for generic entry and price erosion
• Indication expansion probability and launch timing
• Trial outcome probabilities and regulatory timelines

Without those inputs, producing a market projection would not be complete or accurate.

---

Key Takeaways

• A complete clinical trials update cannot be delivered without trial-level, registry-verifiable data (phase, status, enrollment, readouts).
• A complete market analysis and 5-year projection cannot be delivered without current market sizing inputs and exclusivity/generic-entry timing.
• Deflazacort’s market behavior depends primarily on generic penetration, reimbursement/formulary status, and prescriber persistence in chronic systemic steroid use.

FAQs

1. What is deflazacort used for?
   It is an oral systemic corticosteroid used in inflammatory and immune-mediated conditions requiring glucocorticoid therapy.

2. Does deflazacort have specific advantages versus other steroids?
   Market perception often centers on tolerability and dosing considerations, but comparative advantage depends on indication, population, and local prescribing norms.

3. How does generic competition affect deflazacort revenue?
   It typically drives volume growth while compressing unit revenue through price erosion and formulary switching.

4. What matters most for market growth going forward?
   Formularies and reimbursement coverage plus the timing of generic entry and any indication expansions.

5. What determines the timing of clinical trial impact on the market?
   Trial phase progression, readout timing, and regulatory approval timelines by geography and indication.

---

References

1. No sources were provided in the input, and no external trial registry or market dataset citations were supplied.